Abstract: Cinacalcet, a calcimimetic drug, has been shown to be efficacious in adult chronic kidney disease (CKD) patients; however, it was not fully studied in pediatric CKD patients. We aimed at assessing the effect of cinacalcet on intact parathyroid hormone (iPTH) secretion in children with CKD-4/5 with iPTH consistently 300 pg/mL refrac-tory to conventional treatment. This is a prospective cohort analysis of 28 children with uncon-trolled hyp to a tertia Twent regarding andmedic with CKD with CKD automated and 18 ye All pa Highly sig levels was (P), and C with no h almost in Cinaca patients w most of th (Medicine Abbrev blood u receptor filtration hormo
Introduction Secondary hyperparathyroidism (SHPT) develops in patients with chronic renal failure. C...
Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Unti...
With the aim to expand the randomized controlled trial evidence of cinacalcet treatment to the unsel...
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease...
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease...
Introduction — Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney diseas...
Background: This randomized phase 3 study evaluated the efficacy and safety of cinacalcet in childre...
Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney diseas...
Cinacalcet has proven effective in the treatment of secondary hyperparathyroidism (SHPT) in dialysis...
Background Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease (...
Introduction: Therapy with vitamin D3 analogs suppress the parathyroid hormone (PTH) secretion in ch...
BackgroundCalcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels in people who ha...
A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercal ...
The effects of cinacalcet in persistent and/or hypercalcaemia-associated secondary hyperparathyroidi...
BACKGROUND Secondary hyperparathyroidism (SHPT) may persist after renal transplantation (RTx), in...
Introduction Secondary hyperparathyroidism (SHPT) develops in patients with chronic renal failure. C...
Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Unti...
With the aim to expand the randomized controlled trial evidence of cinacalcet treatment to the unsel...
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease...
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease...
Introduction — Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney diseas...
Background: This randomized phase 3 study evaluated the efficacy and safety of cinacalcet in childre...
Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney diseas...
Cinacalcet has proven effective in the treatment of secondary hyperparathyroidism (SHPT) in dialysis...
Background Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease (...
Introduction: Therapy with vitamin D3 analogs suppress the parathyroid hormone (PTH) secretion in ch...
BackgroundCalcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels in people who ha...
A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercal ...
The effects of cinacalcet in persistent and/or hypercalcaemia-associated secondary hyperparathyroidi...
BACKGROUND Secondary hyperparathyroidism (SHPT) may persist after renal transplantation (RTx), in...
Introduction Secondary hyperparathyroidism (SHPT) develops in patients with chronic renal failure. C...
Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Unti...
With the aim to expand the randomized controlled trial evidence of cinacalcet treatment to the unsel...